Jpmorgan Chase & CO I Mab Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.18 - $3.06 $140,985 - $365,605	-119,479 Reduced 20.0%	477,895 $630,000
Q2 2023 Aug 11, 2023	BUY	$2.95 - $3.85 $109,383 - $142,754	37,079 Added 6.62%	597,374 $1.79 Million
Q1 2023 May 11, 2023	SELL	$3.08 - $7.39 $669,130 - $1.61 Million	-217,250 Reduced 27.94%	560,295 $1.94 Million
Q4 2022 Feb 13, 2023	BUY	$3.22 - $4.86 $2.48 Million - $3.75 Million	771,682 Added 13161.9%	777,545 $3.25 Million
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $974,867 - $3 Million	-243,109 Reduced 97.65%	5,863 $24,000
Q2 2022 Aug 11, 2022	BUY	$8.27 - $18.43 $1.1 Million - $2.45 Million	132,835 Added 114.38%	248,972 $2.81 Million
Q1 2022 May 11, 2022	BUY	$12.54 - $46.93 $1.43 Million - $5.34 Million	113,787 Added 4842.0%	116,137 $1.89 Million
Q4 2021 Feb 10, 2022	SELL	$45.28 - $74.5 $1.08 Million - $1.78 Million	-23,940 Reduced 91.06%	2,350 $111,000
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $1.5 Million - $2.22 Million	26,290 New	26,290 $1.91 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.